A practical reference on HPLC-UV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-29. Anything still debated is marked as such rather than presented as settled.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
The alkali metals consist of the chemical elements lithium (Li), sodium (Na), potassium (K), rubidium (Rb), caesium (Cs), and francium (Fr). Together with hydrogen they constitute group 1, which lies in the s-block of the periodic table. All alkali metals have their outermost electron in an s-orbital: this shared electron configuration results in them having very similar characteristic properties. Indeed, the alkali metals provide the best example of group trends in properties in the periodic table, with elements exhibiting well-characterised homologous behaviour. This family of elements is also known as the lithium family after its leading element. The alkali metals are all shiny, soft, highly reactive metals at standard temperature and pressure and readily lose their outermost electron to form cations with charge +1. They can all be cut easily with a knife due to their softness, exposing a shiny surface that tarnishes rapidly in air due to oxidation by atmospheric moisture and oxygen (and in the case of lithium, nitrogen). Because of their high reactivity, they must be stored under oil to prevent reaction with air, and are found naturally only in salts and never as the free elements. Caesium, the fifth alkali metal, is the most reactive of all the metals. All the alkali metals react with water, with the heavier alkali metals reacting more vigorously than the lighter ones.
Klein C, Entian KD (1994). "Genes involved in self-protection against the lantibiotic subtilin produced by Bacillus subtilis ATCC 6633". Appl. Environ. Microbiol. 60 (8): 2793–801. Bibcode:1994ApEnM..60.2793K. doi:10.1128/aem.60.8.2793-2801.1994. PMC 201725. PMID 8085823. JJ; Roelse, J; Howard, JC; Butcher, GW; Hämmerling, GJ; Neefjes, JJ (1994). "Selectivity of MHC-encoded peptide transporters from human, mouse and rat". Nature. 367 (6464): 648–51. Bibcode:1994Natur.367..648M. doi:10.1038/367648a0. PMID 8107849. Binet R, Letoffe S, Ghigo JM, Delepelaire P, Wandersman C (1997). "Protein secretion by Gram-negative bacterial ABC exporters-a review". Gene. 192 (1): 7–11. doi:10.1016/S0378-1119(96)00829-3. PMID 9224868.
=== 19th and early 20th centuries === Lithium was first used in the 19th century as a treatment for gout after scientists discovered that, at least in the laboratory, lithium could dissolve uric acid crystals isolated from the kidneys. The levels of lithium needed to dissolve urate in the body, however, were toxic. Because of prevalent theories linking excess uric acid to a range of disorders, including depressive and manic disorders, Carl Lange in Denmark and William Alexander Hammond in New York City used lithium to treat mania from the 1870s onwards. By the turn of the 20th century, as theory regarding mood disorders evolved and so-called "brain gout" disappeared as a medical entity, the use of lithium in psychiatry was largely abandoned; however, several lithium preparations were still produced for the control of renal calculi and uric acid diathesis. As accumulating knowledge indicated a role for excess sodium intake in hypertension and heart disease, lithium salts were prescribed to patients for use as a replacement for dietary table salt (sodium chloride). This practice and the sale of lithium itself were both banned in the United States in February 1949, following the publication of reports detailing side effects and deaths.
=== Status === Mesocarb is almost unknown in the western world and is neither used in medicine nor studied scientifically to any great extent outside of Russia and other countries in the former Soviet Union. It has however been added to the list of drugs under international control and is a scheduled substance in most countries, despite its multiple therapeutic applications and reported lack of significant abuse potential.
uraninite (also called pitchblende, the most common uranium ore), UO2 with some U3O8 carnotite, K2(UO2)2(VO4)2·3H2O autunite, Ca(UO2)2(PO4)2·10–12H2O uranophane, Ca(UO2)2(SiO3OH)2·5H2O davidite, (La,Ce,Ca)(Y,U)(Ti,Fe3+)20O38 or (Ce,La)(Y,U)(Ti,Fe3+)20O38 torbernite, Cu[(UO2)(PO4)]2·12H2O coffinite, U(SiO4)1−x(OH)4x Significant concentrations of uranium occur in some substances such as phosphate rock deposits, and minerals such as lignite, and monazite sands in uranium-rich ores (it is recovered commercially from sources with as little as 0.1% uranium).
Sources: en.wikipedia.org
Half & Half is an American television sitcom created by Jeffrey Klarik and executive-produced by Yvette Lee Bowser through her Sister Lee Productions banner that aired on UPN from September 23, 2002, to May 15, 2006 (related to the Fox comedy show, Living Single that aired out in 1993 until 1998). It was co-produced by CBS Studios under one of its former aliases, Eye Productions, Inc. Set in San Francisco, California, the show centers on the lives of two paternal half-sisters in their early adulthood who were estranged throughout their childhood, and are finally developing a close relationship. The show was the second-most-watched on UPN's Monday night line-up (next to Girlfriends) and fourth overall on the network. The series was almost renewed for a fifth season by UPN's successor network, The CW, but due to several circumstances — including the network's contractual obligation to pick up Reba, the last-minute renewal of All of Us, and the pick-up of the Girlfriends spin-off The Game — the series was left off the network's Autumn 2006 schedule and canceled. Outside of the United States, the series has aired in reruns on Global TV in Canada, Trouble in the United Kingdom and in local syndication channels in the United States, including Bounce TV, TV One, Cleo TV, BET Her and Dabl. The series is available to stream on Paramount+ and Amazon Prime Video.
==== Social Democratic Party of Germany ==== At the first party conference of the re-established SPD, held in Leipzig from 22 to 25 February 1990, the party adopted its basic programme and election manifesto centred on the promotion of an ecologically oriented social market economy.
== Structure == Ergothioneine is a thiourea derivative of the betaine of histidine and contains a sulfur atom bonded to the 2-position of the imidazole ring. Typical of thioureas, ergothioneine is less reactive than typical thiols such as glutathione towards alkylating agents like maleimides. It also resists oxidation by air. However, ergothioneine can be slowly oxidized over several days to the disulfide form in acidic solutions.
== External links == 16S rRNA, BioMineWiki Archived 2019-04-27 at the Wayback Machine Ribosomal Database Project II Archived 2020-08-19 at the Wayback Machine Ribosomal+RNA at the U.S. National Library of Medicine Medical Subject Headings (MeSH) SILVA rRNA Database Project (also includes Eukaryotes (18S) and LSU (23S/28S)) Video: rRNA: sequence, function & synthesis Halococcus morrhuae (archaebacterium) 5S rRNA
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.